Comparative Pharmacology
Head-to-head clinical analysis: LIQUID PRED versus NEOMYCIN SULFATE TRIAMCINOLONE ACETONIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LIQUID PRED versus NEOMYCIN SULFATE TRIAMCINOLONE ACETONIDE.
LIQUID PRED vs NEOMYCIN SULFATE-TRIAMCINOLONE ACETONIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prednisolone is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators (cytokines, prostaglandins, leukotrienes).
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Triamcinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, thereby decreasing prostaglandin and leukotriene synthesis, and exerts anti-inflammatory, antipruritic, and vasoconstrictive effects.
5-60 mg/day orally in divided doses; typical starting dose 5-10 mg every 6-12 hours.
Topical: Apply thin film to affected area 2-4 times daily. Otic: Instill 3-4 drops into ear canal 2-3 times daily. Not for systemic use.
None Documented
None Documented
2.1–3.5 hours (terminal elimination half-life; shorter half-life in children; prolonged in hepatic impairment).
Neomycin: 2-3 hours (normal renal function); in renal impairment, prolonged up to 12-24 hours. Triamcinolone acetonide: 2-5 hours (terminal).
Primarily renal: prednisolone is excreted as glucuronide and sulfate conjugates; less than 1% unchanged. Biliary/fecal excretion accounts for <5%.
Neomycin: >90% orally administered excreted unchanged in feces; absorbed fraction (3-6%) excreted renally with 50% within 24 hours. Triamcinolone acetonide: primarily hepatic metabolism, renal excretion of metabolites (~40% as 11-keto derivatives), fecal excretion ~20%.
Category C
Category D/X
Corticosteroid
Corticosteroid